The cholinergic deficiency syndrome and its therapeutic implications

Gerontology

Volumn 49, Issue 1, 2003, Pages 55-60

  Lemstra, Afina W ^a   Eikelenboom, Piet ^a   Van Gool, Willem A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cholinergic deficiency; Dementia; Hypothesis

Indexed keywords

ATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; RIVASTIGMINE; SCOPOLAMINE; TACRINE;

ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; ANXIETY; ATTENTION DEFICIT DISORDER; CHOLINERGIC ACTIVITY; CHOLINERGIC DEFICIENCY SYNDROME; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; CHOLINESTERASE INHIBITION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; ELECTROENCEPHALOGRAM; HALLUCINATION; HISTOPATHOLOGY; HUMAN; IMAGING SYSTEM; MENTAL CONCENTRATION; NEUROCHEMISTRY; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPSYCHIATRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; NEURODEGENERATIVE DISEASES;

EID: 0037211169     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066508     Document Type: Review

References (51)

1. National Institute for Clinical Excellence: Guidance on the Use of Donepezil, Rivastigmine and Galantamine for the Treatment of Alzheimer's Disease. http://www.nice.org.uk.
2. Birks JS, Melzer D, Beppu H: Donepezil for mild and moderate Alzeheimer's disease (Cochrane Review); in The Cochrane Library, Issue 1, 2001. Oxford: Update Software.
3. Olin J, Schneider L: Galantamine for Alzheimer's disease (Cochrane Review); in The Cochrane Library, Issue 1, 2001. Oxford: Update Software.
4. Birks J, Grimley EJ, Iakovidou V, Tsolaki M: Rivastigmine for Alzheimer's disease (Cochrane Review); in The Cochrane Library, Issue 1, 2001. Oxford: Update Software.
5. Committee for Proprietary Medical Products. Eurpean Public Assessment Report of Rivastigmine. http://www.eudra.org/emea.html.
6. Hutchinson M, Fazzini E: Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:324-325.
7. Aarsland D, Bronnick K, Karlsen K: Donepezil for dementia with Lewy bodies: A case study. Int J Geriatr Psychiatry 1999;14:69-72.
8. McKeith J, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sian A, Ferrara R, Spiegel R: Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036.
9. Kaufer DI, Catt KE, Lopez OL, DeKosky ST: Dementia with Lewy bodies: Response of delirium-like features to donepezil. Neurology 1998;51:1512.
10. Francis PT, Palmer AM, Snape M, Wilcock GK: The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-147.
11. Drachman DA, Leavitt J: Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974;30:113-121.
12. Mesulam MM: The systems-level organization of cholinergic innervation in the cerebral cortex and its alterations in Alzheimer. Prog Brain Res 1996;109:285-298.
13. Selden NR, Gitelman DR, Salamon-Murayama N, Parrish TB, Mesulam MM: Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 1998;121:2249-2257.
14. Davies P, Maloney AJ: Selective loss of central cholinergic neurons in AD. Lancet 1976;ii:1403.
15. Bowen DM, Smith CB, White P, Davison AN: Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976;99:459-496.
16. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE: Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 1977;34:247-265.
17. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR: Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982;215:1237-1239.
18. Mesulam MM, Geula C: Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: Observations based on the distribution of acetylcholinesterase and choline acetyl-transferase. J Comp Neurol 1988;275:216-240.
19. Ladner CJ, Lee JM: Pharmacological drug treatment of Alzheimer disease: The cholinergic hypothesis revisited. J Neuropathol Exp Neurol 1998;57:719-731.
20. Coyle JT, Price DL, DeLong MR: Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983;219:1184-1190.
21. Dringenberg HC: Alzheimer's disease: More than 'a cholinergic disorder' - Evidence that cholinergic-monaminergic interactions contribute to EEG slowing and dementia. Behav Brain Res 2000;115:235-249.
22. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V: Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999; 281:1401-1406.
23. Gilmor ML, Erickson JD, Varoqui H, Hersh LB, Bennett DA, Cochran EJ, Mufson EJ, Levey AI: Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 1999;411:693-704.
24. Minger SL, Honer WG, Esiri MM, McDonald B, Keene J, Nicoll JA, Carter J, Hope T, Francis PT: Synaptic pathology in prefrontal cortex is present only with severe dementia in Alzheimer disease. J Neuropathol Exp Neurol 2001;60:929-936.
25. Selkoe DJ: Alzheimer's disease: Genes, proteins and therapy. Physiol Rev 2001;81:741-766.
26. Liberini P, Valerio A, Memo M, Spano PF: Lewybody dementia and responsiveness to cholinesterase inhibitors: A paradigm for heterogeneity of Alzheimer's disease? Trends Pharmacol Sci 1996;17:155-160.
27. Maurer K, Volk S, Gerbaldo H: Auguste D and Alzheimer's disease. Lancet 1997;349:1546-1549.
28. Albert ML: Subcortical dementia; in Katzman et al (eds): Alzheimer's Disease: Senile Dementia and Related Disorders. New York, Raven Press, 1978, pp 173-180.
29. Cummings JL: Introducion; in Cummings JL (ed): Subcortical Dementia. New York, Oxford University Press, 1990, pp 3-16.
30. Sarter M, Bruno JP: Cognitive functions of cortical acetylcholine: Toward a unifying hypothesis. Brain Res Rev 1997;23:28-46.
31. Perry E, Walker M, Grace J, Perry R: Acetylcholine in mind: A neurotransmitter correlate of consciousness? Trends Neurosci 1999;22:273-280.
32. Nakano I, Hirano A: Parkinson's disease: Neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 1984;15:415-418.
33. Perry EK, Morris CM, Court JA, Cheng A, Fairbairn AF, McKeith IG, Irving D, Brown A, Perry RH: Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology. Neuroscience 1995;64:385-395.
34. Perry EK, Perry RH: Acetylcholine and hallucinations: Disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 1995;28:240-258.
35. Forstl H, Burns A, Levy R, Cairns N, Luthert P, Lantos P: Neuropathological correlates of behavioural disturbance in confirmed Alzheimer's disease. Br J Psychiatry 1993;163:364-368.
36. Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, Fairbairn AF, Ince PG, Morris CM, Cheng AV: Cholinergic transmitter and neurotrophic activities in Lewy body dementia: Similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 1993;7:69-79.
37. Levy R, Eagger S, Griffiths M, Perry E, Honavar M, Dean A, Lantos P: Lewy bodies and response to tacrine in Alzheimer's disease. Lancet 1994;343:176.
38. Whitehouse PJ, Hedreen JC, White CL 3rd, Price DL: Basal forebrain neurons in the nucleus of Meynert in dementia of Parkinson's disease. Ann Neurol 1983;13:243-248.
39. Goetz CG, Pappert EJ, Blasucci LM, Stebbins GT, Ling ZD, Nora MV, Carvey PM: Intravenous levodopa in hallucinating Parkinson's disease patients: High-dose challenge does not precipitate hallucinations. Neurology 1998;50: 515-517.
40. Schwab RS, Faing HD, Prichard JS: Psychiatric symptoms and syndromes in Parkinson's disease. Am J Psychiatry 1951;107:901-907.
41. Pourcher E: Cholinesterase inhibitor trial in neurobehavioral disorders associated with Parkinsonism (abstract). Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, 2000, p 224.
42. Korzcyn AD: Dementia in Parkinson's disease. J Neurol 2001;248(suppl 3):1-4.
43. Korczyn AD: Hallucinations in Parkinson's disease. Lancet 2001;358:1031-1032.
44. Forrer GR, Miler JJ: Atropine coma: A somatic therapy in psychiatry. Am J Psychiatry 1958;115:455-458.
45. Itil T, Fink M: Anticholinergic drug-induced delirium: Experimental modification, quantitative EEG and behavioral correlations. J Nerv Ment Dis 1966;143:492-507.
46. Callaway EBRI III: Some psychopharmacological effects of atropine. Arch Neurol Psychiatry 1958;79:91-102.
47. Tune LE, Egeli S: Acetylcholine and delirium. Dement Geriatr Cogn Disord 1999;10:342-344.
48. Trzepacz PT: Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Semin Clin Neuropsychiatry 2000;5:132-148.
49. Kikuchi M, Wada Y, Nanbu Y, Nakajima A, Tachibana H, Takeda T, Hashimoto T: EEG changes following scopolamine administration in healthy subjects. Quantitative analysis during rest and photic stimulation. Neuropsychobiology 1999;39:219-226.
50. Stewart DJ, MacFabe DF, Vanderwolf CH: Cholinergic activation of the electrocorticogram: Role of the substantia innominata and effects of atropine and quinuclidinyl benzilate. Brain Res 1984;322:219-232.
51. McPherson DW, Greenbaum M, Luo H, Beets AL, Knapp FF Jr: Evaluation of Z-(R,R)-IQNP for the potential imaging of m2 mAChR-rich regions of the brain and heart. Life Sci 2000;66:885-896.